Pharma Marketletter - Promising new data for Lilly's Alimta.
Posted on Monday, July 28 @ 07:00:00 CDT by admin
July 28, 2003 -- Results from a Phase III study, published in the Journal of Clinical Oncology, demonstrate that Eli Lilly's Alimta (pemetrexed), in combination with cisplatin, is associated with superior survi
Click Here to read the entire article...
|
| |
|